|
Tavapadon Posts Positive Phase 2 Results in Early Parkinson Disease
|
|
Positive results of a phase 2 assessment of oral tavapadon, previously known as PF-06649751, in patients with early-stage Parkinson disease, have been announced by Cerevel Therapeutics. |
|
Read more
|
|
|
| Siponimod Delays Time to Wheelchair in Secondary Progressive MS |
|
A new analysis of the EXPAND study population has suggested that siponimod (Mayzent, Novartis) may have an additional long-term benefit for patients with secondary progressive multiple sclerosis (MS) beyond the study’s core findings. |
|
Read more
|
|
|
